ArriVent BioPharma (AVBP) Current Assets (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Current Assets data on file, last reported at $348.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 87.69% year-over-year to $348.7 million; the trailing twelve-month figure through Mar 2026 stood at $348.7 million (up 87.69% YoY), and the FY2025 full-year result was $332.9 million, up 46.66% from the prior year.
• Current Assets improved to $348.7 million in Q1 2026, from $332.9 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $348.7 million in Q1 2026 to a low of $160.0 million in Q4 2023.
• A 4-year average of $275.4 million and a median of $300.5 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets sank 43.27% in 2025 and jumped 87.69% in 2026, its largest moves.
• Tracing AVBP's Current Assets over 4 years: stood at $160.0 million in 2023, then jumped by 41.89% to $227.0 million in 2024, then surged by 46.66% to $332.9 million in 2025, then gained by 4.75% to $348.7 million in 2026.
• Business Quant data shows AVBP's Current Assets at $348.7 million in Q1 2026, $332.9 million in Q4 2025, and $321.2 million in Q3 2025.